ConductScience.org, home

Paper279296

Mechanisms of reduction of antitumor drug toxicity by liposome encapsulation.

Rahman YE and 4 others. Ann N Y Acad Sci, 1978. Cited by 19 papers, by iCite.

Cite this record

ConductScience Library. Mechanisms of reduction of antitumor drug toxicity by liposome encapsulation. Papers, record 279296. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/279296

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Mechanisms of reduction of antitumor drug toxicity by liposome encapsulation.
PubMed
Journal
Ann N Y Acad Sci
PubMed
Year
1978
PubMed
Publication types
Journal Article, Research Support, U.S. Gov't, Non-P.H.S.
PubMed
Citations, by iCite
19
iCite
Relative citation ratio, by iCite
0.68
iCite
Revised in PubMed
2019-06-16
PubMed

Authors5

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Rahman YEY E
2Hanson WRW R
3Bharucha JJ
4Ainsworth EJE J
5Jaroslow BNB N

Source PubMed

Download CSV of authors

Topics8

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
DactinomycinMajor topic
LiposomesMajor topic
Animals
Antibody Formation
Bone Marrow
Intestinal Mucosa
Mice
Spleen

Source PubMed

Download CSV of topics

Cited by10

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 19 citations.

PMIDTitleJournalYearIn PapersSource
39861690Liposomal Formulation of Hydroxychloroquine Can Inhibit Autophagy In Vivo.Pharmaceutics2024https://conductscience.org/library/papers/39861690PubMed
23620664Clinical significance of metallothioneins in cell therapy and nanomedicine.Int J Nanomedicine2013https://conductscience.org/library/papers/23620664PubMed
22866157Synergistic antitumor effects of liposomal honokiol combined with cisplatin in colon cancer models.Oncol Lett2011https://conductscience.org/library/papers/22866157PubMed
18350317Liposomal honokiol, a promising agent for treatment of cisplatin-resistant human ovarian cancer.J Cancer Res Clin Oncol2008https://conductscience.org/library/papers/18350317PubMed
7860226Phase I and pharmacologic study of liposomal daunorubicin (DaunoXome).Invest New Drugs1994https://conductscience.org/library/papers/7860226PubMed
7506649Liposomes as carriers of cancer chemotherapy. Current status and future prospects.Drugs1993https://conductscience.org/library/papers/7506649PubMed
7218338Thermodynamics of partitioning and efflux of phenothiazines from liposomes.J Membr Biol1981https://conductscience.org/library/papers/7218338PubMed
7073945Effect of liposomally trapped antitumour drugs on a drug-resistant mouse lymphoma in vivo.Br J Cancer1982https://conductscience.org/library/papers/7073945PubMed
6940195Use of anionic liposomes for the reduction of chronic doxorubicin-induced cardiotoxicity.Proc Natl Acad Sci U S A1981https://conductscience.org/library/papers/6940195PubMed
389479Potential of liposomes as drug-carriers in cancer chemotherapy: a review.Cancer Chemother Pharmacol1979https://conductscience.org/library/papers/389479PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/279296

GET https://conductscience.org/api/papers/v1/279296/authors